title: Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
abstract: BACKGROUND
  Treatment of moderate to severe atopic dermatitis (AD) is often inadequate.
  
  
  OBJECTIVE
  We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD.
  
  
  METHODS
  Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index.
  
  
  RESULTS
  Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 (P < .05) during 8 to 29 weeks of treatment. There were no adverse events.
  
  
  CONCLUSIONS
  Small sample size, lack of placebo control group, and the possibility of bias are limitations.
  
  
  CONCLUSIONS
  The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Lauren L
authors.initials: LL
authors.lastname: Levy
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Urban
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: Brett.King@yale.edu.
authors.forename: Brett A
authors.initials: BA
authors.lastname: King
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003876:Dermatitis, Atopic / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D053612:Janus Kinases
keywords: Janus kinase inhibitor; atopic dermatitis; tofacitinib